Login / Signup

Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.

Athanasios D AnastasilakisStergios A PolyzosMaria P YavropoulouCharikleia NtentiStylianos MandanasPolyzois Makras
Published in: Endocrine (2021)
Keyphrases
  • bone mineral density
  • low dose
  • giant cell
  • postmenopausal women